Research article · 30 Jan 2025
PerspectivePublished 15 Feb 2022
Semaglutide Single Dose Pen-Injector
Mills-Peninsula Medical Center, San Mateo, California, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Subcutaneous semaglutide, delivered by a single-dose pen-injector at a maintenance dose of 2.4mg once weekly, is approved in the USA for weight management in people with a body mass index (BMI) of 30 kg/m2 or higher, or with a BMI of 27 kg/m2 or higher and a minimum of one obesity-related co-morbidity. The semaglutide single-dose pen-injector could be a shield-activated auto-injector. Auto-injectors were at the start developed for emergency use however are used for chronic conditions for many years and for glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment for type 2 diabetes disease (T2D) since 2014. Shield activation entails the discharge of the injection by pushing the pen-injector against the patient's skin, as hostile activation via a button.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Obesity and Metabolism.
Perspective · 31 Dec 2024
The Long-Term Outlook after Bariatric Revision Surgery
Opinion · 31 Dec 2024
The Impact of Metabolic Syndrome on Cardiovascular Health and Disease Prevention
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Obesity and Metabolism
- SubjectDiabetes & Endocrinology
- SubjectObesity & Weight Management
- BylineArticles whose byline prints “Mohd Yaser”
